LTR Pharma Taps Nick Bell to Support Digital Health and Commercial Growth
LTP: $0.410 +0.00% · MC: $86M
LTR Pharma has appointed entrepreneur Nick Bell as a strategic adviser, with an initial focus on introductions to telehealth platforms, clinic networks and commercial partners. He will also help evaluate scalable, compliant patient-access pathways for SPONTAN and KYZATREX in Australia; the appointment is intended to strengthen the company’s digital-health and commercial capabilities.

Comments